NCT02060604

Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration

A Randomised Controlled Trial of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Università degli Studi di Brescia · Academic / Other
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

The addition of an anti-inflammatory agent could be a valid option for controlling choroidal neovascularization, as simply inhibiting VEGF addresses neither the multifactorial pathogenesis of choroidal neovascularization nor the underlying cause of VEGF production.

Conditions

• Wet Macular Degeneration

Interventions

Type	Name	Description
DRUG	Ketorolac + Ranibizumab	3 monthly ranibizumab, then as needed Ketorolac TID
DRUG	Ranibizumab	3 monthly ranibizumab, then as needed

Timeline

• Start date: 2012-12-01
• Primary completion: 2014-01-01
• Completion: 2014-01-01
• First posted: 2014-02-12
• Last updated: 2014-02-12

Locations

1 site across 1 country: Italy